Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services

Alice Panchaud, PharmD PhD¹,²,³, Valentin Rousson, PhD⁴, Thierry Vial, MD⁵, Nathalie Bernard, PharmD⁵, David Baud, MD PhD⁶, Emmanuelle Amar, MD⁷, Marco De Santis, MD⁸, Alessandra Pistelli, MD⁹, Anne Dautriche, MD¹⁰, Frederique Beau-Salinas, MD¹¹, Matteo Cassina, MD¹², Hannah Dunstan, PhD¹³, Anneke Passier, PhD¹⁴, Yusuf Cem Kaplan, MD¹⁵, Mine Kadioglu Duman, MD¹⁶ Eva Maňáková, MD¹⁷, Georgios Eleftheriou, MD¹⁸, Gil Klinger, MD¹⁹, Ursula Winterfeld, PhD², Laura E. Rothuizen, MD², Thierry Buclin, MD², Chantal Csajka, PhD¹, Sonia Hernandez-Diaz, MD, DrPH³

¹School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland; ²Swiss Teratogen Information Service (STIS) and Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland; ³Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; ⁴Institute of Social and Preventive Medicine (IUMSP), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; ⁵Pharmacovigilance Center of Lyon, Hospices Civils de Lyon, France; ⁶Materno-Fetal and Obstetrics Research Unit, Departement “Femme-Mere-Enfant”, University Hospital, Lausanne, Switzerland; ⁷Registre des Malformations en Rhone Alpes (REMERA), Faculté Laennec, Lyon, France; ⁸Telefono Rosso-Teratology Information Service, Department of Obstetrics and Gynecology, Catholic University of Sacred Heart, Rome, Italy; ⁹Centro di Riferimento Regionale di Tossicologia Perinatale, SODc Tossicologia Medica, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy; ¹⁰Pharmacovigilance Center of Dijon, CHU, Dijon, France; ¹¹Pharmacovigilance Center of Tours, CHRU, Tours, France; ¹²Teratology Information Service, Clinical Genetics Unit, Department of Women’s and Children’s health, University of Padova, Padova, Italy; ¹³UQTIS, Regional Drug and Therapeutics Centre, Newcastle upon Tyne, UK; ¹⁴Teratology Information Service (TIS), Netherlands Pharmacovigilance Centre Lareb, The Netherlands; ¹⁵Izmir Katip Celebi University, Faculty of Medicine Department of Pharmacology Teratology Information Service, Izmir, Turkey; ¹⁶Karadeniz Technical University, Faculty of Medicine, Department of Pharmacology, Trabzon, Turkey; ¹⁷CZTIS, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; ¹⁸Poison Control Center, Bergamo, Italy; ¹⁹BELTIS Rabin Medical Center and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel.

Abstract

Background: Metformin is used to treat type 2 diabetes, polycystic ovary syndrome associated infertility, and gestational diabetes. Human studies evaluating the safety of metformin in early pregnancy are scarce.

Method: We evaluated the risk of major birth defects and pregnancy losses in a cohort of pregnant women exposed to metformin during first trimester for different indications relative to a matched unexposed reference group.

Results: The risk of major birth defects was 5.1% (20/392) in pregnancies exposed to metformin during the first trimester and 2.1% (9/431) in the reference group (adjusted odds ratio (OR) 1.70; 95%CI 0.70-4.38). Among metformin users, this risk was 7.8% (17/219) in patients with pre-gestational diabetes and 1.7% (3/173) in those without this diagnosis. Compared to the unexposed reference, the OR for metformin user with diabetes was 3.95 (95% CI 1.77-9.41) and for metformin with other indications it was 0.83 (95% CI 0.18-2.81). The risk of pregnancy losses (spontaneous abortions and stillbirths) was 20.8% in women on metformin during the first trimester and 10.8% in the reference group (adjusted hazard ratio (HR) 1.57; 95%CI 0.90-2.74). The risks for women on metformin with and without pre-
gestational diabetes were 24.0% and 16.8% respectively, with adjusted HR of 2.51 (95%CI 1.44-4.36) and 1.38 (95%CI 0.74-2.59) when compared to the reference.

**Conclusion:** Pregnant women with pre-gestational diabetes on metformin are at a higher risk for adverse pregnancy outcomes than the general population. This appears to be due to the underlying diabetes since women on metformin for other indications do not present meaningfully increased risks.

Contact: alice.panchaud@chuv.ch